Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trial.

ABSTRACT:

Background

The Arise-FJ-G005 study compared the efficacy and safety of perioperative camrelizumab and apatinib combined with chemotherapy with those of perioperative chemotherapy alone for locally advanced gastric cancer (LAGC) and assessed its effect on major pathological response (MPR). Herein, we report the 3-year survival outcomes of this trial.

Methods

Arise-FJ-G005 was a multicenter, open-label, phase 2, randomized controlled trial (NCT04195828), conducted between June 2020 and March 2022. Patients with LAGC (clinical T2-4, N+, M0) were randomly assigned to receive perioperative CA-SAP (camrelizumab and apatinib combined with nab-paclitaxel plus S-1 [SAP]) or SAP alone for three cycles preoperatively and five cycles postoperatively. The primary endpoint was the MPR. Th

SUBMITTER: Lin JX 

PROVIDER: S-EPMC12546971 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature